This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Hemispherx Not Among 4 to Get H1N1 Flu Contracts

Hemispherx Biopharma (HEB - Get Report) has been shut out of the U.S. government's efforts to stockpile vaccine against the H1N1 flu.

Four companies were awarded contracts Monday totaling just under $900 million to supply ingredients for a potential H1N1 vaccine. U.S. Health and Human Services Secretary Kathleen Sebelius announced the contracts, which went to Novartis (NVS), GlaxoSmithKline (GSK), Sanofi-Aventis (SNY) and AztraZeneca (AZN).

Hemispherx wasn't necessarily in the running for a U.S. flu contract, but the company has sought, in recent weeks, to promote itself to investors as a player in the global effort to develop an effective vaccine against the latest strain of the flu.

Hemispherx CEO Bill Carter claims international partners, including vaccine makers in Japan, are interested in using Hemispherx's drug Ampligen as an adjuvant flu vaccine booster.

In an interview with a penny-stock promoter published last month, Carter said, in reference to Ampligen: "The highest level of the Japanese government and public medical community is now focused exclusively on our product. They stopped working on all other adjuvants (boosters) and are only working with this one because they've found that it enhances the vaccines by 100 fold."

But Hemispherx hasn't announced a single flu contract to date; nor has the company provided any independent corroboration of its claims that partners are actively working today to develop Ampligen as a vaccine adjuvant.

What the company has done, instead, is recycle old clinical data for use in new press releases touting Ampligen's use as a flu vaccine booster.

Carter's talk of Ampligen and flu vaccines is more likely yet another attempt to divert attention away from the problems the company is having getting Ampligen approved as a treatment for chronic fatigue syndrome (CFS).
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
HEB $0.14 0.00%
AAPL $95.18 0.00%
FB $117.43 0.00%
GOOG $692.36 0.00%
TSLA $232.32 0.00%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs